"Constand Pharmaceuticals: Fumagillol thalidomide injection approved for clinical trials of new drugs"

Hengrui Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for the injection of Fumarsuan Taigeleding, and will conduct clinical trials in the near future. The drug is an injection and is approved for clinical trials for pain relief in critically ill patients receiving mechanical ventilation. It is a -opioid receptor biased small molecule agonist, which is expected to be approved for domestic marketing in January 2024, with a total research and development investment of approximately 199 million yuan. The drug research and development and market launch cycle is long, with many uncertainties.